Publications

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

Journal:
Science translational medicine, Volume: 5, Issue: 214
Published:
December 4, 2013
PMID:
24307692
Authors:
Srinivasa P S Rao SP, Suresh B Lakshminarayana SB, Ravinder R Kondreddi RR, Maxime Herve M, Luis R Camacho LR, Pablo Bifani P, Sarath K Kalapala SK, Jan Jiricek J, Ng L Ma NL, Bee H Tan BH, Seow H Ng SH, Mahesh Nanjundappa M, Sindhu Ravindran S, Peck G Seah PG, Pamela Thayalan P, Siao H Lim SH, Boon H Lee BH, Anne Goh A, Whitney S Barnes WS, Zhong Chen Z, Kerstin Gagaring K, Arnab K Chatterjee AK, Kevin Pethe K, Kelli Kuhen K, John Walker J, Gu Feng G, Sreehari Babu S, Lijun Zhang L, Francesca Blasco F, David Beer D, Margaret Weaver M, Veronique Dartois V, Richard Glynne R, Thomas Dick T, Paul W Smith PW, Thierry T Diagana TT, Ujjini H Manjunatha UH
Access Paper
Abstract:

New chemotherapeutic compounds against multidrug-resistant Mycobacterium tuberculosis (Mtb) are urgently needed to combat drug resistance in tuberculosis (TB). We have identified and characterized the indolcarboxamides as a new class of antitubercular bactericidal agent. Genetic and lipid profiling studies identified the likely molecular target of indolcarboxamides as MmpL3, a transporter of trehalose monomycolate that is essential for mycobacterial cell wall biosynthesis. Two lead candidates, NITD-304 and NITD-349, showed potent activity against both drug-sensitive and multidrug-resistant clinical isolates of Mtb. Promising pharmacokinetic profiles of both compounds after oral dosing in several species enabled further evaluation for efficacy and safety. NITD-304 and NITD-349 were efficacious in treating both acute and chronic Mtb infections in mouse efficacy models. Furthermore, dosing of NITD-304 and NITD-349 for 2 weeks in exploratory rat toxicology studies revealed a promising safety margin. Finally, neither compound inhibited the activity of major cytochrome P-450 enzymes or the hERG (human ether-a-go-go related gene) channel. These results suggest that NITD-304 and NITD-349 should undergo further development as a potential treatment for multidrug-resistant TB.

Courtesy of the U.S. National Library of Medicine